AqVida features hi-tech manufacturing at CPhI Frankfurt
Press Release | AqVida GmbH
OCTOBER 16, 2017
Hamburg, Germany: – Innovative German oncology generics specialist AqVida will make its highly advanced new robotic filling site at Dassow the star of its show at Europe’s leading pharma trade show, CPhI Worldwide.
The Hamburg-based oncology manufacturer, which is dedicated to development, registration, manufacturing and licensing/distribution of oncology generics, will once again be an exhibitor at CPHI 2017 in Frankfurt, with its own stand (Booth 91A63) in the new FDF (Finished Dosage Formulations) zone at Messe Frankfurt.
AqVida will use the show to present the manufacturing and efficiency advantages that the Dassow plant will unlock for clients with its automotive, flexible) and lean production systems.
The striking ‘laboratory’ look of the AqVida stand at CPhI Frankfurt is largely due to use of cleanroom panels from Dubai-based MRC Cleanroom Systems, who will be a co-exhibitor on the stand. MRC cleanroom technology is an important element in the highly innovative new AqVida production facility near Hamburg.
Audio-visual displays will allow stand visitors to experience the new plant’s highly advanced automated, robotic filling and finishing capabilities, as well as its data-driven methodology.
The new “Zero Loss” facility features unique engineering technology to manufacture parenteral oncology generics and antibody drug conjugates (ADCs). This facility represents a major step forward for the pharma industry, using totally robotic controlled filling processes in an isolator for parenteral cytotoxics.
Latest Development: Sunitinib
“All in all, AqVida comes to CPhI Worldwide 2017 with a stronger offer than ever to our EU and non EU clients: very high quality ‘Made in Germany’ generic oncology injectables, with spare and free EU Marketing approvals available, backed by full registration support. In addition, our new plant allows us to back all that up with a highly responsive and flexible supply capacity,” commented AqVida’s Commercial Director, Jürgen Lehmberg.
AqVida will also present the first of its New Generic Generation of oral generic oncology drugs. Sunitinib is a generic version of Sutent® that is expected to receive EU marketing approval shortly.
“This year, we will give Sunitinib capsules high priority, with EMA regulatory procedures running well and first MA approvals expected before the end of this year,” Mr. Lehmberg added.
“CPHI Worldwide is the most important pharma event of the year for AqVida,” said Mr. Lehmberg.
“This is especially true for 2017, with the show returning to Germany, our home market, and once again being staged in Frankfurt, where we first exhibited on our own stand in 2013,” Mr. Lehmberg noted.
“CPhI gives us the ideal platform from which to meet clients, both existing and potential, and deepen our business relationships,” he noted.
AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.
AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio.
AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.
AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.
About CPhI Worldwide 2017
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors networking opportunities with potential international pharmaceutical partners and collaborators, as well as latest industry insights.
Now in its 28th year, CPhI 2017 is a three-day event opening October 24 at the Messe Frankfurt exhibition center. Last year’s event in Barcelona attracted some 42,000 delegates and more than 2,500 exhibitor companies from 155 countries worldwide.
CPhI Worldwide is held alongside four other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, InnoPack pharmaceutical packaging and a new addition, the FDF show for Finished Dosage Formulations, bringing together every aspect of the dosage supply chain.
The CPhI Pharma Awards, presented on the first evening of the conference, honor innovative companies and leaders.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: www.cphi.com/europe/
Jürgen Lehmberg, Commercial Director, AqVida GmbH
Wolfgang Heinze, CEO, AqVida GmbH
Tel: +49 40 380 37190
Click on AqVida features hi-tech manufacturing at CPhI Frankfurt for other information.
Click on AqVida to contact the company directly.
Click on AqVida brochure for more information.
Click on AqVida at CPhI for stand details.